Q1 2026 Champions Oncology Inc Earnings Call Transcript
Key Points
- Champions Oncology Inc (CSBR) achieved $14 million in revenue for Q1 fiscal 2026, marking a rebound from the previous quarter's softness.
- The company's TOS business led growth, with significant contributions from the emerging data platform.
- The radiopharmaceutical services platform is expanding, reducing costs and improving gross margins by bringing work in-house.
- The data platform has generated sales for three consecutive quarters, leveraging the PDX Bank to create a comprehensive tumor data set.
- Champions Oncology Inc (CSBR) remains debt-free with a positive operating cash flow, providing financial flexibility.
- Revenue for Q1 fiscal 2026 was flat compared to the same quarter last year, indicating a lack of year-over-year growth.
- The company recorded a loss from operations of $0.5 million on a GAAP basis, compared to income from operations in the previous year.
- Gross margin declined to 43% from 50% in the same quarter last year, primarily due to increased outsourced lab service costs.
- Operating expenses increased by $1 million from the previous year, driven by higher R&D, sales and marketing, and G&A costs.
- The macro environment remains challenging, with biotech funding and R&D budgets under pressure, impacting customer spending.
Welcome to the Champions Oncology first quarter fiscal year 2026 earnings call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Rob Brainin, Chief Executive Officer. You may begin.
Good afternoon. I'm Rob Brainin, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Thank you for joining our quarterly earnings call.
Before we begin, I'll remind you that today's remarks may include forward-looking statements. Actual results may differ materially, and more information can be found in our filings with the SEC. As many of you know fiscal 2025 is a pivotal year for Champions as we rebounded after a difficult 2024 to achieve record annual revenue and profitability. Now, as we move into fiscal year 2026, I'm honored to step into the role of leading Champions forward. My focus is on building on the strong foundation, sharpening strategic execution, and positioning Champions for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
